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ABSTRACT
To assess the efficacy and safety of non-biological
therapies in patients with axial spondyloarthritis
(axSpA) to inform the update of the Assessment of
SpondyloArthritis international Society (ASAS)/
European League Against Rheumatism (EULAR)
recommendations for the management of axSpA. A
systematic literature review (2009–2016) of all non-
pharmacological treatments, non-biological drugs
(except targeted synthetic disease-modifying
antirheumatic drugs (DMARDs)) and surgical therapies
was performed. Randomised controlled trials (RCTs)
and clinical controlled trials were assessed for efficacy
and safety, while observational studies with a
comparator were assessed for safety. All relevant
efficacy and safety outcomes were included. Study
heterogeneity precluded data pooling. If possible,
Cohen’s effect size was calculated for
non-pharmacological treatments. In total, 45 papers
and 2 abstracts were included. Studies on
non-pharmacological treatments were very
heterogeneous but overall confirmed a benefit for
regular exercises, with small improvements in disease
activity, function and spinal mobility. New studies on
non-steroidal anti-inflammatory drugs (NSAIDs)
confirmed their efficacy and new safety signals were
not found. NSAIDs used continuously compared with
on-demand did not reduce the modified Stoke
Ankylosing Spondylitis Spinal Score (mSASSS) mean
change over 2 years in patients with ankylosing
spondylitis with normal C reactive protein (CRP;
≤5 mg/L) (1 ‘negative’ RCT (0.9 vs 0.8; p=0.62)),
while for patients with high CRP, conflicting results
were found (1 ‘positive’ RCT (0.2 vs 1.7; p=0.003),
1 ‘negative’ RCT (1.68 vs 0.96; p=0.28)). No new trials
were found for conventional synthetic DMARDs
(csDMARDs). Short-term high-dose systemic
glucocorticoids showed limited efficacy. Regular
exercises may improve several outcomes. Efficacy and
safety of NSAIDs in axSpA are confirmed.
Glucocorticoids are not proven to be effective in axSpA
and new data on csDMARDs are lacking.
INTRODUCTION
Treatment of axial spondyloarthritis (axSpA)
can be a challenge due to a limited number
of therapeutic alternatives.1 In the past
decade, a plethora of non-pharmacological
and pharmacological therapies have been
applied, aiming to improve the patient’s
quality of life, to reduce pain and physical
impairment and to avoid work disability.
Treatment with tumour necrosis factor α
inhibitors (TNFi) is especially efﬁcacious but
because of drug cost treatment has been
reserved for patients failing the so-called con-
ventional compounds such as non-steroidal
anti-inﬂammatory drugs (NSAIDs).2 Overall,
a multidisciplinary approach with a combin-
ation of non-pharmacological and pharmaco-
Key messages
▸ Regular exercises may improve several
outcomes.
▸ Efficacy and safety of NSAIDs in axSpA are
confirmed.
▸ Glucocorticoids are not proven to be effective in
axSpA.
▸ No new data on csDMARDs in axSpA was found.
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logical treatment and, if needed, a surgical intervention
comprises the full spectrum of the treatment of axSpA.2
A collaboration between the Assessment of
SpondyloArthritis international Society (ASAS) and the
European League Against Rheumatism (EULAR) has led
to the ﬁrst publication of the ASAS/EULAR recommenda-
tions for the management of ankylosing spondylitis (AS)
in 2006,1 while an update had been published in 2010,2
based on evidence from systematic literature reviews
(SLRs).3 4 In these recommendations, treatment was con-
strained to patients in later stages of axSpA (radiographic
axSpA—r-axSpA—or AS). Another ASAS initiative issued
recommendations for the use of TNFi in patients with
axSpA, also taking the earlier, non-radiographic stages
(nr-axSpA) into account.5 Still, no recommendations had
yet covered the whole management spectrum (including
non-pharmacological and pharmacological management)
and the full spectrum of axSpA (including both nr-axSpA
and r-axSpA). During the past years, accumulating evi-
dence has shown that the disease is one continuum,
including nr-axSpA and r-axSpA.6 This, together with the
progress witnessed in the area of management of axSpA in
the past years, justiﬁed an update of the recommendations
for the management of axSpA.
The objective of the current SLR was to update the
evidence on efﬁcacy and safety of non-biological inter-
ventions (non-pharmacological treatment, non-
biological drugs and surgical therapies). This SLR was
performed together with another on biological and tar-
geted synthetic disease-modifying antirheumatic drugs
(tsDMARDs).7 8 Both SLRs aimed to inform the task
force responsible for the update of the ASAS/EULAR
recommendations for the management of axSpA.9
METHODS
Search methodology and study selection
The systematic literature search was performed by using
references from MEDLINE, EMBASE and Cochrane
CENTRAL databases and as an update of the previous
SLR conducted in 2009.4 The articles included in the
present SLR had to be published between 1 January
2009 and 26 February 2016. In addition, abstracts from
the annual conferences of EULAR and the American
College of Rheumatology (ACR) 2014 and 2015 were
included. The search strategy is presented in online
supplementary text 1. Eligible study types for efﬁcacy
and safety assessment were randomised controlled trials
(RCTs), clinical controlled trials (CCTs) and open-label
long-term extension studies. Cohort studies or registries
were considered for safety assessment but only if a com-
parator treatment was available, or if population-based
incidence rates were reported and at least 50 partici-
pants per group were included. For surgical interven-
tions, cohort studies with a comparator group, as well as
case–control studies, were used to assess both efﬁcacy
and safety. SLRs were only considered appropriate to
identify references from original studies, except for
Cochrane reviews, which were included anyway.
Research questions were reformulated according to the
PICO (Participants, Interventions, Comparisons and
Outcomes) method.10 Studies were selected with adult
patients (age ≥18 years) and a diagnosis of axSpA. The
interventions in the current SLR were deﬁned as (1)
non-pharmacological interventions (physiotherapy, exer-
cise, balneotherapy, spa therapy, diet, education, self-
education groups), (2) non-biological drugs, such as
NSAIDs, local and systemic glucocorticoids, conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs) (methotrexate, leﬂunomide, sulfasalazine,
hydroxychloroquine, azathioprine, cyclosporine, cyclo-
phosphamide, auranoﬁn, penicillamine or thalidomide),
bisphosphonates, analgesics, opioids, opioid-like drugs,
neuromodulators (antidepressants, anticonvulsants and
muscle relaxants) and probiotics, and (3) surgical ther-
apies. All doses, formulations, regimens (eg, on-demand,
continuous) and treatment durations were assessed.
Treatment comparators were deﬁned as any non-
pharmacological or surgical intervention, same non-
biological interventions in different doses or regimens,
other non-biological drugs, any combination therapy,
placebo or none.
Outcomes considered for the assessment of treatment
efﬁcacy were the Bath AS Disease Activity Index
(BASDAI11), Bath AS Functional Index (BASFI12), Bath
AS Metrology Index (BASMI13), AS Disease Activity
Score (ASDAS14 15) and ASDAS disease activity status,16
ASAS partial remission,17 patient’s global assessment of
disease activity, pain levels, assessments of enthesitis,
swollen and tender joint count. Outcomes considered
for patient’s response to treatment were the ASAS
response criteria17 (ASAS20, ASAS40 and ASAS5/6),18
ASDAS clinically important improvement (Δ≥1.1) and
ASDAS major improvement (Δ≥2.0)16 and BASDAI
response (improvement of ≥50% and/or ≥2 units). The
AS Quality of Life (ASQoL19) index was considered to
evaluate the Quality of Life. Additionally, work disability,
work productivity, cost-efﬁcacy and cost-effectiveness were
assessed. Radiographic progression of the spine was
assessed by the modiﬁed Stoke Ankylosing Spondylitis
Spinal Score (mSASSS20). Inﬂammation on magnetic res-
onance imaging (MRI) was measured by the ASAS/
Outcome Measures in Rheumatology (OMERACT) deﬁn-
ition21 and the Spondyloarthritis Research Consortium of
Canada (SPARCC) score (sacroiliac joints22 and spine23).
For safety outcomes, information was collected on
withdrawals due to adverse events (AEs), serious AEs,
infections, malignancies, cardiovascular disease, infu-
sion/injection-site reactions, renal, gastrointestinal (GI)
and hepatic effects, haematological abnormalities and
demyelinating disease.
Data extraction and assessment of risk of bias (RoB)
Each article or abstract identiﬁed was assessed independ-
ently by two reviewers (AR and AS) for suitability accord-
ing to the predeﬁned inclusion criteria, followed by a
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full-text review. For every included study, relevant data
were extracted. Additionally, the two reviewers evaluated
the RoB of each study according to the ‘Cochrane tool’
for RCTs,24 the ‘Hayden-tool’ for cohort studies25 and
the Newcastle-Ottawa Scale for case–control studies.26
Disagreements regarding the eligibility of the studies,
data extraction and RoB assessment were resolved by dis-
cussion and consensus. In case of persistent disagree-
ment, a third reviewer (SR) was involved.
Data analysis
Owing to the large heterogeneity of the studies, data
could not be pooled and results are presented descrip-
tively. As in the previous SLR,4 if possible, Cohen’s effect
size (ES) (mean change in score divided by the base-
line standard deviation (SD)) was calculated for non-
pharmacological interventions, with Cohen’s ES<0
meaning worsening, 0–0.49 a small positive effect (ie,
improvement), 0.5–0.79 a moderate effect and ≥0.8 a
large effect. Additionally, if possible, the number
needed to treat (NNT, number of patients who must be
treated in order to obtain the beneﬁt of interest in one
additional patient) was presented.
RESULTS
Overall, the search yielded 11 649 articles (after
de-duplication), of which 45 full-text articles and 2
abstracts were included in this SLR (ﬂow chart in online
supplementary ﬁgure S1 and online supplementary tables
S1–S4; the articles on biological DMARDs and tsDMARDs
are included in a separate SLR8). In total, 29 trials investi-
gated beneﬁts and harms of non-pharmacological therap-
ies (28 papers;27–54 1 abstract55), 15 publications focused
on non-biological drugs (13 papers;56–68 1 abstract;69 1
Cochrane review70), and 3 articles71–73 assessed the efﬁ-
cacy of surgical interventions.
No studies were found on csDMARDs, neuromodula-
tors, diet or self-education groups.
Non-pharmacological interventions
Twenty-nine trials were identiﬁed assessing different
non-pharmacological interventions in patients with
axSpA (for details, see online supplementary tables S5–
S9 (Exercises), S10–S14 (Education), and S15–S19
(Other non-pharmacological interventions)).27–55
Overall, the studies were heterogeneous (ﬁgure 1),
differing mainly in the type and duration of interven-
tion, group size and outcome parameters. The group
size was often small: only four studies44–46 50 included
more than 90 patients. One study51 enrolled patients
with active axSpA deﬁned according to the ASAS classiﬁ-
cation criteria and with a BASDAI≥3.5.6 All the remain-
ing studies focused on patients with established r-axSpA
according to the modiﬁed New York (mNY) criteria.
Nine studies28 29 34 42 44 45 49 51 53 had a low or
unclear RoB and we have therefore focused on these,
Figure 1 Characteristics of the included trials on non-pharmacological treatment. ASDAS, Ankylosing Spondylitis Disease
Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index;
BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; ROM,
range-of-motion exercises; SF-36, short-form health survey 36.
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Table 1 Cohen’s effect size for several outcomes of non-pharmacological interventions
Study ID Intervention n
Classification
criteria
Duration of
intervention
(weeks) Primary end point BASDAI BASFI BASMI
Pain
global ASDAS
Risk of
bias
Exercises/rehabilitation
Dundar 201434 Aquatic exercises 35
mNY 4 NR
0.68 0.34 0.48 0.96 –
Unclear
Land-based exercises 34 0.52 0.39 0.42 0.57 –
Kjeken 2013*42 Rehabilitation programme 29
mNY 3 BASDAI (+) BASFI (−) – – – – – Unclear
‘treatment as usual’ 34 – – – – –
Niedermann 201344 Nordic walking+flexibility 53
mNY 12
Physical work capacity
on bicycle (+)
0.24 –0.07 0.18 – –0.29
Unclear
Attention control+flexibility 53 0.21 0.00 0.07 – 0.07
Sveaas 201451 Endurance+strength training 10
ASAS 2009† 12 ASDAS (−) 1.43 0.50 0.20 – 0.83 Unclear
No exercises 24 0.08 0.00 0.06 – 0.13
Education
Rodriguez-Lozano 201345 Education+exercises 381
mNY 24
BASDAI (+)
BASFI (+)
0.28 0.22 – 0.27 –
Unclear
Standard care‡ 375 0.16 0.08 – 0.15 –
Other non-pharmacological interventions
Annegret 201328 Radon Spa therapy 20
mNY 4 Pain (VAS 0–10) (+)
– 0.12 – – –
Low
Tap water baths 19 – 0.05 – – –
Aydin 2013*29 Low-level laser therapy 19
mNY 2 NR
– – – – –
Unclear
Placebo laser 18 – – – – –
Stasinopoulos 201649 Laser therapy+stretching 24
mNY 8 NR
– 0.84 – 2.48 –
Unclear
Placebo laser+stretching 24 – –0.11 – 0.12 –
Turan 2014*53 Magnetotherapy+exercises 35
mNY 2
Harris hip assessment
index (−)
– – – – –
Low
Placebo magnetotherapy 31 – – – – –
(+): Positive trial; (−): negative trial.
Only studies with a low or an unclear risk of bias are presented.
*Cohen’s effect size could not be calculated for 3 studies as the results are not shown as mean (SD).
†Active axSpA (BASDAI≥3.5).
‡Pharmacological and non-pharmacological interventions.
ASAS, Assessment of SpondyloArthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; mNY, modified New York criteria; NR, not reported;
SD, standard deviation; VAS, visual analogue scale.
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that is, we excluded the high RoB studies from in-depth
analysis. An overview of these low/unclear RoB studies,
together with Cohen’s ES for BASDAI, BASFI, pain
global and ASDAS, can be found in table 1. In summary,
regular exercises can improve disease activity, pain, func-
tion and spinal mobility. However, the effects were
usually small. Endurance combined with strength train-
ing, compared with ‘no exercises’, provided the largest
effect on disease activity, both measured with the ASDAS
(mean 2.3 vs 2.7 at start and 1.8 vs 2.6 at the end of
observation, respectively) and BASDAI (mean 5.3/10 vs
5.3/10 units at start and 3.3 vs 5.2 at the end of observa-
tion, respectively).51 Laser therapy compared with
placebo resulted in the largest effect on function as mea-
sured by the BASFI (mean 51.5/100 vs 48.6/100 at start
and 37.4/100 vs 50.6/100 at the end of observation,
respectively) and pain (mean 70.0/100 vs 67.5/100 at
start and 33.1/100 vs 65.6/100 at the end of observation,
respectively) (Cohen’s ES of 0.84 for BASFI and 2.48 for
pain, both for Laser therapy, respectively).49 Aquatic
exercises compared with land-based exercises led to the
best improvements in pain (mean 5.1/10 vs 4.9/10 at
start and 2.6/10 vs 3.3/10 at the end of observation,
respectively) (Cohen’s ES of 0.96 for aquatic exercises),
also with moderate improvements in BASDAI (at start
mean 3.9/10 vs 4.0/10 and 2.6/10 vs 2.8/10 at the end
of observation, respectively; Cohen’s ES 0.68).34
Five studies31 32 43 48 54 focused on a combination
therapy of exercises and TNFi compared with treatment
of TNFi only. However, none of these studies showed any
additional effect on the function and spinal mobility of
patients with axSpA by exercises added to TNFi therapy.
Non-biological drugs
The main characteristics and efﬁcacy data of the
included studies on non-biological drugs are presented
in tables 2 and 3; safety data from observational studies
are shown in table 4. Additional data as well as the RoB
assessment are presented in online supplementary tables
S20–S24 for efﬁcacy and S25–S27 for safety.
Non-steroidal anti-inflammatory drugs
A Cochrane review,70 comparing NSAIDs (traditional
and cyclooxygenase (COX)-II inhibitors) to placebo as
well as between them, included 39 studies (35 RCTs, 2
quasi-RCTs, 2 cohorts) up to June 2014. From the
studies included in the Cochrane review, only two
studies were published in or after 2009 (Poddubnyy
et al,74 Kroon et al59), thus overlapping with the current
SLR. Both focused on the effect of NSAIDs on radio-
graphic progression. This Cochrane review showed that
after 6 weeks of treatment, traditional NSAIDs and
COX-II inhibitors were more efﬁcacious than placebo
(pain visual analogue scale (VAS) 0–100: −16.5 (95% con-
ﬁdence interval (CI) −20.8 to −12.2) with traditional
NSAIDs (mean 44/100) versus placebo (mean 60.5), NNT
4 (range 3–6); −21.7 (95% CI −35.9 to −7.4), with COX-II
inhibitors (mean 42.3) versus placebo (mean 64), NNT 3
(range 2–24)). Moreover, no measurable differences were
seen between the different NSAIDs. No signiﬁcant
increase in AEs at 12 weeks were reported for NSAIDs.
In addition, ﬁve RCTs addressing NSAIDs were
included in this SLR (tables 2 and 3), two of them focus-
ing on the effect of NSAIDs on radiographic
progression.58 59 Two studies comparing two NSAIDs
(table 2, see online supplementary tables S20–S24) were
included in the current SLR. Both studies56 69 con-
ﬁrmed the results of the aforementioned Cochrane
review.70 The ﬁrst study,69 at unclear RoB, showed that
two different doses of etoricoxib (ETX) were as effective
as naproxen (NPX) in improving the spinal pain inten-
sity (SPI) score on a VAS (0–100) in patients with
r-axSpA (SPI least square mean change from baseline at
week 6: −29.0 for ETX 60 mg, −31.2 for ETX 90 mg,
−30.6 for NPX 1000 mg). The second study,56 also at
unclear RoB, demonstrated non-inferiority of celecoxib
compared with diclofenac in decreasing the patient’s
global assessment of pain intensity on a 0–100 scale
(mean change at week 6: −23.7 celecoxib 200 mg, −26.7
diclofenac 75 mg).
The third trial (at high RoB) showed a small beneﬁt
favouring ‘palisade sacroiliac joint radiofrequency neur-
otomy’ in improving the global pain intensity compared
with celecoxib (table 2).57
The other two RCTs58 59 focused on radiographic pro-
gression. Sieper et al58 2016, at low RoB, evaluated the
effect of diclofenac on spinal radiographic progression
in patients with r-axSpA when taken continuously versus
on-demand (table 3). No signiﬁcant differences in the
mSASSS mean change over 2 years were found, either in
the whole group (1.28 vs 0.79; p=0.39, respectively) or in
the subgroup with elevated C reactive protein (CRP) at
baseline (1.68 vs 0.96; p=0.28). In contrast, Kroon et al59
(at low RoB) found a signiﬁcant difference between con-
tinuous use of celecoxib versus on-demand in patients
with r-axSpA with elevated CRP at baseline (0.2 vs 1.6;
p=0.003; favouring continuous use). Study characteristics
on both studies are provided in online supplementary
table S20.
Two observational studies60 61 were identiﬁed assessing
the safety of NSAIDs in axSpA (table 4 and online
supplementary tables S25–S27). Only one study,
Kristensen et al,60 at moderate RoB, focused on GI AEs.
No differences in their incidence were found when com-
paring COX-II inhibitors with traditional NSAIDs.
However, a signiﬁcantly reduced risk of GI-AEs was iden-
tiﬁed in patients not using NSAIDs compared with
patients on traditional NSAIDs.
Essers et al,61 at moderate RoB, reported a larger risk of
ischaemic heart disease in patients with r-axSpA using
NSAIDs (adjusted hazard ratio (aHR) (95% CI) 1.36
(1.00 to 1.85)) or COX-II inhibitors (aHR (95% CI) 3.03
(1.61 to 5.69)) compared with the general population.
Kristensen et al60 also looked at atherosclerotic events and
found no signiﬁcant differences between traditional
NSAIDs and COX-II inhibitors (at moderate RoB).
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Table 2 Efficacy of non-biological drugs (RCTs and CCTs)
Study ID Intervention n
Classification
criteria Study design Primary end point
Primary end
point in each
group
p
Value
Time point of
primary end
point
Primary end
point met?
Risk of
bias
NSAIDs
Balazcs ACR 201569 Naproxen 1000 mg/day 143
mNY Non-inferiority trial, RCT
Δ Spinal pain intensity
(VAS 0–100)
−30.6 NR
6 weeks (+) UnclearEtoricoxib 60 mg/day 660 −29.0 NR
Etoricoxib 90 mg/day 144 −31.2 NR
Huang 201456 Celecoxib 200 mg/day 117
mNY Non-inferiority trial, RCT
Δ PatGA of pain
intensity (VAS 0–100)
−23.7 (20.6) NR
6 weeks (+) Unclear
Diclofenac 75 mg/day 115 −26.7 (22.9) NR
Zheng 201457 Palisade sacroiliac joint radiofrequency
neurotomy
82
mNY RCT
Global pain intensity
(VAS 0–10)
2.5 (2.2; 3.0) NR
12 weeks (+) High
Celecoxib 400 mg/day 73 4.4 (4.0; 4.9) NR
Sieper 201558 Diclofenac continuous 150 mg/day† 62
mNY RCT Δ mSASSS
1.28 (0.7; 1.9)
0.39 2 years (−) Low
Diclofenac on-demand 60 0.79 (0.2; 1.4)
Kroon 201259 Celecoxib continuous 200 mg/day 52 mNY
+CRP>5 mg/L*
Post hoc analysis of
Wanders 200582 (RCT)
Δ mSASSS
0.2 (1.6)
0.003 2 years (+) Low
Celecoxib on-demand 45 1.7 (2.8)
Glucocorticoids
Haibel 201462 Placebo 13
mNY Placebo-controlled RCT BASDAI 50
8.0% Ref
2 weeks (−) LowPrednisolone 20 mg/day 11 27.0% 0.30
Prednisolone 50 mg/day 12 33.0% 0.16
Other non-biological drugs
Chang 201364 Tramadol 37.5 mg/acetaminophen 325 mg
+aceclofenac 100 mg (2 times/day)
30
mNY Placebo-controlled RCT ASAS20
53.3%
0.047 12 weeks (+) High
Placebo+aceclofenac 100 mg (2 times/day) 30 31.0%
Sarkar 201265 Pamidronate 60 mg intravenously monthly 66
Amor Placebo-controlled CCT ASAS20
63.6% NR
6 months NR High
Placebo 21 NR NR
Jenks 201066 Probiotics (about 0.8 g 2 times/day) 32
ESSG Placebo-controlled RCT BASFI
2.9 (1.9)
0.839 12 weeks (−) Low
Placebo 31 3.1 (2.2)
Liu 201467 Xinfeng capsule (1.5 g 3 times/day) 60
ASAS axSpA RCT NS
NR NR
NR NR High
Sulfasalazine (1 g 2 times/day) 60 NR NR
Wang 201368 Jitongning capsule (0.5 g 3 times/day) 58
mNY RCT ASAS20
72.4%
NS NR‡ (−) High
Sulfasalazine (1 g 2 times/day) 53 67.9%
ASAS 2009 classification criteria.6
Risk of bias according to the Cochrane tool.24
Amor classification criteria.79
(+): Positive trial; (−): negative trial; Δ: change between baseline and follow-up.
*The results are just shown for this subgroup.
†At least 75 mg/day diclofenac has been taken by every patient; switching to another NSAID was allowed.
‡At both time points (6 and 12 months) no significant differences between both groups in the ASAS20.
ACR, American College of Rheumatology; ASAS, Assessment of SpondyloArthritis international Society; ASAS20, 20% improvement according to the ASAS response criteria; axSpA, axial
spondyloarthritis; BASDAI 50, 50% improvement of the initial Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CCT, clinical controlled
trial; CRP, C reactive protein; ESSG, European Spondyloarthropathy Study Group;80 mNY, modified New York criteria;81 mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NR, not
reported; NS, not significant; NSAID, non-steroidal anti-inflammatory drug; PatGA, patient’s global assessment; RCT, randomised controlled trial; VAS, visual analogue scale.
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Glucocorticoids
Two studies examined the efﬁcacy and safety of gluco-
corticoids in r-axSpA (tables 2 and 4 and online
supplementary tables S20–S24 and S25–S27).
One RCT62 (at low RoB), Haibel et al (table 2) per-
formed in patients with r-axSpA with active disease
(BASDAI≥4) has shown no short-term differences
between two different doses of prednisolone and
placebo in the primary end point (BASDAI 50 week 2:
8% under placebo; 27% under prednisolone 20 mg, p
value versus placebo=0.30; 33% under prednisolone
50 mg, p value versus placebo=0.16). However, there
were signiﬁcant effects observed on ASDAS-CRP (week 2
change scores: −0.34 for placebo; −1.16 for prednisol-
one 20 mg, p value versus placebo=0.004; −1.56 for pred-
nisolone 50 mg, p value versus placebo=0.010) and CRP
(week 2 change scores: −3.19 for placebo; −19.94 for
prednisolone 20 mg, p value versus placebo=0.0016;
−15.58 for prednisolone 50 mg, p value versus
placebo=0.036). The number of AEs at 2 weeks was
similar in the three-arm study (n=6 placebo; n=4 under
prednisolone 20 mg; n=5 under prednisolone 50 mg).
One cohort study63 (at high RoB) assessed the safety
of low-dose glucocorticoids and NSAIDS compared with
NSAIDs alone in patients with r-axSpA (table 4). No sig-
niﬁcant differences were reported for serious infections
and peptic ulcer disease. On the other hand, a higher
incidence of dermatological AEs was found in patients
receiving glucocorticoids (incidence rate/1000 patient-
years 22.2 vs 6.6; p=0.003).
Other non-biological drugs
Five trials (four studies64 65 67 68 at high RoB and one
study66 at low RoB) were identiﬁed assessing the efﬁcacy
and safety of other non-biological drugs such as
probiotics and pamidronate (table 2 and online
supplementary tables S20–S24). In summary, none of
the studies provided convincing evidence that these
therapeutic alternatives are effective.
Surgical interventions
Overall, three studies71–73 (all at high RoB) focusing on
surgical interventions in patients with advanced r-axSpA
were found. These studies suggested beneﬁts for pedicle
subtraction osteotomy and total hip replacement in
patients with a ﬁxed kyphotic deformity or advanced hip
joint deformity, respectively (see online supplementary
tables S28–S31).
DISCUSSION
This SLR summarises the current state of evidence for
non-pharmacological treatments, non-biological drugs
and surgical interventions in the treatment of axSpA,
published after 2009.
The evidence favouring the efﬁcacy of non-
pharmacological interventions such as exercises, educa-
tion and physiotherapy conﬁrmed previous ﬁndings.4
Almost all studies that were analysed demonstrated that
regular exercises may improve disease activity, function,
spinal mobility and pain in patients with axSpA.
However, since the trials were so heterogeneous, no data
pooling could be performed. The absence of a meta-
analysis makes it difﬁcult to decide which type of exer-
cise is preferable, also because improvements were often
small, regardless of the type of intervention. Only one
study51 focused on axSpA according to the ASAS cri-
teria,6 including early and advanced stages of disease,
and required a high disease activity (BASDAI≥3.5) for
inclusion. All remaining trials included patients with
Table 3 Effect of NSAIDs on spinal radiographic progression in patients with r-axSpA
Sieper
201558
All n
mSASSS
Risk of
bias
Baseline mean
(SD) p Value
2 years
mean (SD) p Value
2-years
mean change
(95% CI) p Value
Continuous 62 10.9 (15.5)
0.10
12.2 (16.7)
0.13
1.28 (0.7; 1.9)
0.39
Low
On-demand 60 16.4 (18.2) 17.2 (18.6) 0.79 (0.2; 1.4)
CRP>5 mg/L at baseline
Continuous 34 13.9 (17.9)
0.20
15.6 (19.6)
0.22
1.68 (0.7; 2.6)
0.28
On-demand 35 19.3 (19.0) 20.6 (19.3) 0.96 (0.0; 1.9)
mSASSS
Kroon 201259 n Baseline
mean (SD)
p Value 2 years
mean (SD)
p Value 2-years
mean change (SD)
p Value Risk of
bias
CRP>5 mg/L
LowContinuous 52 7.9 (14.7)
NR
NR
NR
0.2 (1.6)
0.003
On-demand 45 9.3 (15.2) NR 1.7 (2.8)
Bold=significant (p<0.05).
Sieper 2015: Diclofenac continuous (150 mg/day, at least 75 mg/day) versus on-demand (negative trial).
Kroon 2012: Celecoxib continuous (200 mg/day, increase to 400 mg/day was allowed) versus on-demand (positive trial).
CI, confidence interval; CRP, C reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NR, not reported; NSAIDs,
non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; SD, standard deviation.
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Table 4 Safety of non-biological drugs (observational studies)
Study ID Group n
Atherosclerotic events* IHD GI-events
Serious
infections DAE
Risk of
bias
aIR/1000py
(95% CI)
aRR (95%
CI) aHR (95% CI)
aIR/1000py
(95% CI)
aRR (95%
CI) IR/1000py
IR/
1000py
NSAIDs
Kristensen 201560 Etoricoxib 1655 2.9 (1.4; 6.3) 0.8 (0.4; 1.7) NR 9.0 (4.1; 19.7) 1.3 (0.6; 2.7) NR NR
Moderate
Celecoxib 858 2.8 (1.2; 6.3) 0.8 (0.3; 1.7) NR 5.4 (1.8; 15.8) 0.8 (0.3; 2.2) NR NR
Traditional NSAIDs 15 580 3.7 (2.5; 5.4) Ref NR 7.1 (4.6; 10.9) Ref NR NR
Non-user 4260 3.8 (2.6; 5.4) 1.0 (0.7; 1.5) NR 3.4 (2.4; 4.9) 0.5 (0.3; 0.7) NR NR
Essers 201661 General population 25 299 NR NR Ref† NR NR NR NR
Moderate
Any NSAID 1233 NR NR 1.36 (1.00; 1.85) NR NR NR NR
Naproxen 291 NR NR 0.26 (0.04; 1.84) NR NR NR NR
COX-II inhibitors 287 NR NR 3.03 (1.61; 5.69) NR NR NR NR
Traditional NSAID 692 NR NR 1.32 (0.93; 1.89) NR NR NR NR
GC
Zhang 201563 GC+NSAIDs 555 NR NR NR NR NR 4.4 22.6 High
NSAIDs 275 NR NR NR NR NR 4.4 6.6
Bold=significant (p<0.05).
Kristensen 2015: Register-based cohort—r-axSpA and spondyloarthritis; median age in the cohort—46 years; follow-up—2006-2009 (3 years).
Essers 2016: Claims data set—patients with r-axSpA (n=3640) compared with general population (n=25 299); both groups—83% <60 years; follow-up—1987–2012 (25 years).
Zhang 2015: Data from Rheumatology Outpatient Department of the First Affiliated Hospital of Shantou University Medical College in China—r-axSpA (n=830); low-dose GC—10 mg
prednisone/10 mg methylprednisolone; duration mean (SD)—1.7 (1.6) years; NSAIDs—90 mg acemetacin or 50 mg indomethacin or 7.5 mg meloxicam.
*Atherosclerotic events=cardiac and cardiovascular.
†Patients with r-axSpA with or without recent NSAID use were compared with all controls, irrespective of the use of NSAIDs in the control group.
aHR, adjusted HR; aIR, adjusted incidence rate; aRR, adjusted relative risk; CI, confidence interval; COX, cyclooxygenase; DAE, dermatological adverse events; GC, glucocorticoids; GI,
gastrointestinal; IHD, ischaemic heart disease; IR, incidence rate; NR, not reported; NSAID, non-steroidal anti-inflammatory drug; py, patient-years; r-axSpA, radiographic axial spondyloarthritis;
ref, reference.
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advanced r-axSpA. Furthermore, data on the safety of
the exercises were indecisive, since the information
about possible AEs, such as vertebral fractures, was not
available but may be relevant, particularly in advanced
stages of the disease.
Another point of concern is the quality of the studies
on non-pharmacological interventions. Although several
studies were performed during the past years, the overall
RoB was most often ‘high’. One main reason for this is
the lack of blinding of the outcome assessors, which
admittedly is challenging to achieve for some interven-
tions such as physiotherapy or exercises. Still, designing
blinded studies for such interventions is not without pre-
cedent: previous trials, for example, with a sham inter-
vention as a comparator, have shown that interventions
broadly considered to be effective may fail to demon-
strate superiority when tested against a formal compara-
tor, and when blinding is ensured.75
As already shown in the previous SLRs informing
ASAS-EULAR recommendations,4 76 NSAIDs are effect-
ive for the treatment of axSpA with no difference in efﬁ-
cacy between different classes. Compared with the last
SLR, new evidence regarding the effect of NSAIDs on
radiographic progression has been published but the
results are not consistent. Until now, there is no evi-
dence that NSAIDs reduce spinal radiographic progres-
sion in patients with r-axSpA with normal CRP, while
contradicting evidence towards less radiographic pro-
gression is available for patients with elevated CRP and
continuous NSAIDs intake.58 59 In addition, one cohort
study showed an inhibitory effect of continuous NSAID
use on radiographic progression in patients with r-axSpA
and elevated CRP.74 Taken all together, the potential
inhibitory effect of NSAIDs on spinal radiographic pro-
gression is still an open question and warrants more
research to draw deﬁnite conclusions.
In comparison to the previous SLR,4 no new ﬁndings
on the safety of NSAIDs were obtained. Overall, only
four studies with moderate quality could be analysed on
this topic, all together conﬁrming the previous data at
least for patients with established r-axSpA, while eligible
observational studies focusing on safety in patients with
nr-axSpA were not available.
In contrast to the previous SLRs, a low RoB RCT62 has
addressed the short-term efﬁcacy of high doses of sys-
temic glucocorticoids. This study failed to formally dem-
onstrate superior efﬁcacy of glucocorticoids for patients
with r-axSpA with active disease (BASDAI≥4), since it
did not meet its primary end point (BASDAI 50).
However, signiﬁcant differences in secondary outcomes
were found, such as in ASDAS-CRP and CRP levels for
prednisolone 20 mg and 50 mg and in the BASDAI levels
for prednisolone 50 mg as compared with placebo. This
proof-of-concept 2-week trial with high doses of glucocor-
ticoids in axSpA has shown only very modest efﬁcacy.
New trials on other DMARDs were not found in this
SLR. From earlier trials, we have obtained evidence that
DMARDs are not efﬁcacious in axSpA.77 78
Finally, similar to the studies identiﬁed in the last
SLR,4 the level of evidence for surgical interventions
remained low. Only three small studies testing surgical
interventions to a comparator were found. The remain-
ing captured (but not included) studies were case series
or cohort studies without a comparator, thus hampering
the assessment of possible treatment effects. The limited
data suggest that patients with advanced r-axSpA may
beneﬁt from spinal corrective osteotomy or total hip
arthroplasty when indicated.
In summary, in the latest SLR on non-biological treat-
ment in axSpA, the evidence on efﬁcacy and safety of
NSAIDs was conﬁrmed, while no new data were found on
treatment with csDMARDs. Thus far, oral glucocorticoids
did not demonstrate efﬁcacy in axSpA. Regular exercises
may improve outcomes, but with modest effect sizes. This
SLR has informed the 2016 update of the ASAS-EULAR
recommendations for the management of axSpA.
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